Atheroma Reduction with Chloroquine in the Metabolic Syndrome
What is ARCH – MS?
ARCH-MS is a clinical trial looking at the effects of chloroquine, a drug previously approved by the FDA for the treatment of malaria and certain autoimmune diseases, on hardening of the arteries and risk factors for heart disease like pre-diabetes, high blood pressure, and high cholesterol. This study has two parts: AIM 2 and AIM 3. AIM 2 is designed to study whether chloroquine improves blood pressure, cholesterol, and insulin resistance, a form of pre-diabetes. AIM 3 is designed to study whether chloroquine slows the progression of atherosclerosis, or plaque build-up in the arteries. Both AIM 2 and AIM 3 of the ARCH-MS clinical trial are funded by the National Institutes of Health and are being conducted at Washington University in St. Louis.